首页> 外文期刊>European urology >Long-term follow-up of bladder cancer patients with disseminated tumour cells in bone marrow.
【24h】

Long-term follow-up of bladder cancer patients with disseminated tumour cells in bone marrow.

机译:膀胱癌患者骨髓中弥漫性肿瘤细胞的长期随访。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: The clinical relevance of polymerase chain reaction (PCR)-based techniques for detection of disseminated tumour cells (DTCs) in the bone marrow of bladder cancer (BCa) patients is still under debate, as data on long-term follow-up analysis have not yet been published. OBJECTIVE: The aim of the present prospective study was to assess the prognostic significance of DTCs detected by cytokeratin-20 (CK20) reverse-transcriptase PCR in bone marrow from BCa patients undergoing radical cystectomy (RC). DESIGN, SETTING, AND PARTICIPANTS: Bone marrow samples from 51 BCa patients with high-risk non-muscle-invasive or muscle-invasive urothelial carcinoma were drawn from the anterior iliac crest prior to RC. CK20-positive cells in bone marrow were detected by qualitative RT-PCR. MEASUREMENTS: BCa patients with CK20 status were analysed with respect to the end points tumour progression and cancer death. A multivariate Cox regression analysis was performed to determine independent prognostic factors for progression-free survival (PFS), tumour-specific survival (TSS), and overall survival (OS). RESULTS AND LIMITATIONS: CK20-positive cells were detected in 16 of 51 (31.4%) BCa patients of all stages. BCa patients with CK20-negative status displayed a 7-yr PFS rate of 64% versus 35.2% for CK20-positive patients (p=0.007). TSS was significantly shorter in the CK20-positive group, with a 7-yr survival rate of 46.9% compared to CK20-negative patients with 70.2% (p=0.012). The 7-yr OS rate of 37.5% for CK20-positive patients was significantly <65.7% in the CK20-negative group (p=0.006). A subgroup analysis of lymph node-negative patients (pN0) discriminated by CK20 status revealed significant differences in PFS, TSS, and OS. In a multivariate analysis, CK20-status provides independent prognostic information with respect to all three survival end points. CONCLUSIONS: BCa patients with positive CK20 status in bone marrow represent a high-risk subgroup reflected by an unfavourable outcome in the long-term analysis.
机译:背景:基于聚合酶链反应(PCR)的技术对膀胱癌(BCa)患者的骨髓中弥散性肿瘤细胞(DTC)的检测的临床相关性仍存在争议,因为长期随访分析的数据尚未发布。目的:本前瞻性研究的目的是评估通过细胞角蛋白20(CK20)逆转录酶PCR检测到的BCa在行根治性膀胱切除术(RC)的BCa患者中的DTC的预后意义。设计,地点和参与者:在进行RC前,从51前terior抽取51位BCa高危非肌肉侵袭性或肌肉侵袭性尿路上皮癌患者的骨髓样本。通过定性RT-PCR检测骨髓中CK20阳性细胞。测量:对CK20状态的BCa患者进行了肿瘤进展和癌症死亡的终点分析。进行了多变量Cox回归分析,以确定无进展生存期(PFS),肿瘤特异性生存期(TSS)和总体生存期(OS)的独立预后因素。结果与局限性:在所有阶段的51名BCa患者中,有16名(31.4%)检测到CK20阳性细胞。 CK20阴性的BCa患者的7年PFS率为64%,而CK20阳性的患者为35.2%(p = 0.007)。 CK20阳性组的TSS显着缩短,与CK20阴性组的70.2%相比,其7年生存率为46.9%(p = 0.012)。 CK20阴性组的7年OS率为37.5%,在CK20阴性组中显着<65.7%(p = 0.006)。对以CK20状态区分的淋巴结阴性患者(pN0)进行的亚组分析显示,PFS,TSS和OS有显着差异。在多变量分析中,CK20状态提供了关于所有三个生存终点的独立预后信息。结论:在长期分析中,不良的结果反映了骨髓中CK20阳性的BCa患者代表高危亚组。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号